Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00127140
Status:
COMPLETED
Last Update Posted:
2015-09-28
First Post:
2005-08-03
Brief Title:
A Study of Oral Suberoylanilide Hydroxamic Acid SAHA in Patients With Malignant Lymphoma 0683-030
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase I Clinical Study of MK0683 in Patients With Malignant Lymphoma
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this trial is to determine the maximum tolerated dose MTD or the maximum acceptable dose MAD and evaluate the dose limiting toxicity DLT of oral vorinostat in patients with malignant lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_041 | None | None | None |